LATISSE
Google image searchProduct monograph
Active ingredient
bimatoprost, 0.03 %/W/V
DIN: 02350939
Dosage form(s): SOLUTION
Route(s) of administration: TOPICAL
Schedule: Prescription
Company: ABBVIE CORPORATION
Date: 29-AUG-2022
ATC:
- S01 — OPHTHALMOLOGICALS (ATC, ATC/DDD, )
- S01E — ANTIGLAUCOMA PREPARATIONS AND MIOTICS (ATC, ATC/DDD)
- S01EE — Prostaglandin analogues (ATC, ATC/DDD)
- S01EE03 — BIMATOPROST (ATC/DDD)
Reference brand drug: Latisse, Lumigan
